Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 10, 2014, Pages 1426-1433

  Shultz, David Benjamin ^a   Filippi, Andrea Riccardo ^b   Thariat, Juliette ^c   Mornex, Francoise ^c   Loo, Billy W ^a   Ricardi, Umberto ^b  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR;

ADRENAL METASTASIS; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL (TOPIC); EARLY CANCER; HUMAN; LOCAL THERAPY; LUNG CANCER; LUNG METASTASIS; LUNG TUMOR; METASTASIS RESECTION; OLIGOMETASTATIC LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; LUNG NEOPLASMS; METASTASIS; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSURGERY; SECONDARY;

DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; RADIATION DOSAGE; RADIOSURGERY;

EID: 84925823911     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000317     Document Type: Review

References (73)

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10.
2. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011;8:378-382.
3. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012;83:878-886.
4. Lo SS, Moffatt-Bruce SD, Dawson LA, et al. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 2011;8:405-416.
5. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2008;112:650-658.
6. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013;31:1384-1390.
7. Lussier YA, Khodarev NN, Regan K, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One 2012;7:e50141.
8. Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol 2010;33:157-163.
9. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010;375:1030-1047.
10. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
11. Crabtree T, Puri V, Timmerman R, et al. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg 2013;145:692-699.
12. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009;27:1579-1584.
13. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572-1578.
14. Chang HJ, Ko HL, Lee CY, et al. Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using tomotherapy. Radiat Oncol 2012;7:222.
15. Gomez DR, Niibe Y, Chang JY. Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulm Med 2012;2012:396592.
16. Oh D, Ahn YC, Seo JM, et al. Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol 2012;51:596-602.
17. Lopez Guerra JL, Gomez D, Zhuang Y, et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys 2012;84:e61-67.
18. Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 2008;72:398-403.
19. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997;113:37-49.
20. Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the "international registry of lung metastases". J Thorac Oncol 2011;6:1373-1378.
21. Kaifi JT, Gusani NJ, Deshaies I, et al. Indications and approach to surgical resection of lung metastases. J Surg Oncol 2010;102:187-195.
22. Schlijper RC, Grutters JP, Houben R, et al. What to choose as radical local treatment for lung metastases from colo-rectal cancer: surgery or radiofrequency ablation? Cancer Treat Rev 2014;40:60-67.
23. Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer 2012;75:77-81.
24. Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 2004;60:186-196.
25. Brown WT, Wu X, Fowler JF, et al. Lung metastases treated by CyberKnife image-guided robotic stereotactic radiosurgery at 41 months. South Med J 2008;101:376-382.
26. Yoon SM, Choi EK, Lee SW, et al. Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumors. Acta Oncol 2006;45:1108-1114.
27. Onimaru R, Shirato H, Shimizu S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 2003;56:126-135.
28. Okunieff P, Petersen AL, Philip A, et al. Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol 2006;45:808-817.
29. Filippi AR, Badellino S, Guarneri A, et al. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases. Technol Cancer Res Treat 2014;13:37-45.
30. Hof H, Hoess A, Oetzel D, Debus J, Herfarth K. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol 2007;183:673-678.
31. Osti MF, Carnevale A, Valeriani M, et al. Clinical outcomes of single dose stereotactic radiotherapy for lung metastases. Clin Lung Cancer 2013;14:699-703.
32. Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol 2010;5:1091-1099.
33. Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol 2013;107:409-413.
34. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005;8:89-91.
35. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-S100.
36. Trakul N, Chang CN, Harris J, et al. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys 2012;84:231-237.
37. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010;37:4078-4101.
38. A randomised trial of pulmonary metastasectomy in colorectal cancer (PulMiCC). Available at: http://clinicaltrials.gov/ct2/show/NCT01106261. Accessed April 2014.
39. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET). Available at: http://clinicaltrials.gov/ct2/show/NCT01446744?term=NCT01446744&rank=1. Accessed April 2014.
40. Stereotactic body radiotherapy in lung metastases from any non haematological primary cancer (SAFRON II). Available at: http://clinicaltrials.gov/ct2/show/NCT01965223?term=safron+II&rank=1. Accessed April 2014.
41. Stereotactic body radiation therapy (SBRT) in metastatic non-small cell lung cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01185639?term=NCT01185639&rank=1. Accessed April 2014.
42. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis. Br J Cancer 2005;92:1033-1037.
43. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-1431.
44. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-2902.
45. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:4349-4357.
46. Villaruz LC, Kubicek GJ, Socinski MA. Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep 2012;14:333-341.
47. De Ruysscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 2012;7:1547-1555.
48. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 2013;82:197-203.
49. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) non-small cell lung cancer, version 2., 2014. In NCCN Clinical Practice Guidelines in Oncology [Internet]. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed April 2014.
50. Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett GH, Suh JH. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 2006;104:907-912.
51. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280:1485-1489.
52. Soltys SG, Adler JR, Lipani JD, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2008;70:187-193.
53. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009;10:1037-1044.
54. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-1672.
55. Flannery TW, Suntharalingam M, Regine WF, et al. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys 2008;72:19-23.
56. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-141.
57. th Ed. Chicago: Springer Verlag, 2010.
58. Voltolini L, Rapicetta C, Luzzi L, et al. Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup. Eur J Cardiothorac Surg 2010;37:1198-1204.
59. Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2010;140:377-386.
60. Bille A, Pelosi E, Skanjeti A, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 2009;36:440-445.
61. Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008;26:1142-1147.
62. Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011;187:245-251.
63. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
64. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
65. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-3334.
66. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
67. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012;7:1807-1814.
68. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8:346-351.
69. Pemetrexed disodium and carboplatin or cisplatin with or without erlotinib hydrochloride in treating patient with stage IV non-small cell lung cancer resistant to first-line therapy with erlotinib hydrochloride or gefitinib. Available at: http://clinicaltrials.gov/show/NCT01928160. Accessed April 2014.
70. A study of IRESSA treatment beyond progression in addition to chemotherapy versus chemotherapy alone (IMPRESS). Available at: http://clinicaltrials.gov/show/NCT01544179. 2014. Accessed April 2014.
71. A randomized phase II trial of docetaxel, cisplatin, and hypofractionated radiotherapy versus docetaxel and cisplatin for limited volume stage IV non-small cell lung cancer: the synergistic metastases annihilation with radiotherapy and docetaxel (Taxotere) [SMART] trial. Available at: http://clinicaltrials.gov/show/NCT00887315. Accessed April 2014.
72. A randomized phase II study assessing the efficacy of local consolidative therapy for non-small cell lung cancer patients with oligometastatic disease. Available at: http://clinicaltrials.gov/show/NCT01725165. Accessed April 2014.
73. A randomized phase II study of oligometastatic stage IV non-small cell lung cancer (NSCLC) treated with systemic therapy plus either radiotherapy to all sites of gross residual disease or no radiotherapy. Available at: http://clinicaltrials.gov/show/NCT00776100. Accessed April 2014.